#BIO22: Coming together at a critical time, Endpoints News looks at the key metrics on biopharma in a turbulent time

Bioregnum Opinion Column by John Carroll

Back at the beginning of the year during JP Morgan, I came up with my usual set of projections for the year ahead and definitely got one thing wrong. The biotech IPO market, I said in January, would…